Table 1. Characteristics of the Studies Included in the Meta-analysis.
| Source | Country | Cohort size, No. | Age, mean (SD), y | Patients, No. (%) | Onset after vaccination, mean (SD), d | LV systolic dysfunction, No. (%)a | LGE | Outcomes, No. (%) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | Male | BNT162b2 | mRNA-1273 | First dose | Second dose | Mild | Moderate | Severe | Hospitalization | Hospital LOS, mean (SD), d | ICU admission | Inotropes | ECMO | Death | |||||||
| Li et al,19 2022 | Hong Kong | 43 | 14.9 (1.5) | NA | NA | 43 (100) | 0 | 7 (16.3) | 36 (83.7) | NA | NA | NA | NA | NA | 43 (100) | NA | NA | NA | NA | NA | |
| Krug et al,20 2022 | US | 253 | NA | 23 (9.1) | 230 (90.9) | 253 (100) | 0 | 129 (51.0) | 124 (49.0) | NA | NA | NA | NA | NA | 220 (87) | NA | NA | NA | NA | NA | |
| Mevorach et al,21 2022 | Israel | 13 | NA | 1 (0.8) | 12 (92.3) | 13 (100) | 0 | 1 (7.7) | 12 (92.3) | NA | NA | NA | NA | NA | 13 (100) | 3.1 | NA | 0 | NA | NA | |
| Truong et al,22 2022 | US | 139 | 15.8 (14.5-17.0)b | 13 (9.4) | 126 (90.6) | 131 (94.2) | 5 (3.6) | 12 (8.6) | 128 (91.4) | 2 (1-3)b | 22 (16.0) | 2 (1.4) | 2 (1.4) | 74 (76.3) | NA | 2 (2-3)b | 26 (18.7) | 2 (1.4) | 0 | 0 | |
| Foltran et al,23 2022 | 148 countries | 193 | 15.9 (1.3) | 21 (10.9) | 172 (89.1) | 185 (95.9) | 8 (4.1) | 31 (16.1) | 58 (30.1) | 3 | NA | NA | NA | NA | 172 (89.1) | NA | NA | NA | NA | NA | |
| Jain et al,24 2021 | US | 63 | 15.6 (1.8) | 5 (7.9) | 58 (92.1) | 59 (93.7) | 4 (6.3) | 1 (1.6) | 62 (98.4) | 2.1 (1.3) | 9 (14.0) | 0 | 0 | 49 (88.0) | NA | 3 (1.4) | 27 (42.9) | 0 | 0 | 0 | |
| Amir et al,25 2022 | Israel | 15 | 17 (1.0) | 0 | 15 (100) | 15 (100) | 0 | 1 (6.7) | 14 (92.3) | 4.4 (6.7) | 2 (13.3) | 0 | 0 | 14 (93.0) | 13 (86.7) | 4.8 (1.6) | 7 (46.7) | 0 | NA | NA | |
| Nygaard et al,26 2022 | Denmark | 15 | 16 (1.2) | 2 (13.3) | 13 (86.7) | 15 (100) | 0 | 8 (53.3) | 7 (46.7) | NA | 2 (13.0) | 0 | 1 (6.7) | NA | 15 (100) | 3.7 (2.1) | 1 (6.7) | NA | NA | NA | |
| Chelala et al,27 2022 | US | 5 | 17.2 (1.0) | 0 | 5 (100) | 4 (80.0) | 1 (20.0) | 0 | 5 (100) | 3.6 (0.5) | 1 (20.0) | 0 | 0 | 5 (100) | NA | 4.4 (2.3) | NA | NA | NA | 0 | |
| Das et al,28 2021 | US | 25 | 15.3 (1.4) | 3 (12.0) | 22 (88.0) | 25 (100) | 0 | 3 (12.0) | 22 (88.0) | 3.1 (3.6) | 2 (8.0) | 0 | 0 | 15 (93.8) | 22 (88.0) | 2.6 (1.2) | NA | NA | NA | 0 | |
| Roh et al,29 2022 | South Korea | 40 | 16 (14.5-17)b | 14 (35.0) | 26 (65.0) | 40 (100) | 0 | 25 (62.5) | 15 (37.5) | 2 (1-5)b | 6 (15.0) | 0 | 0 | NA | NA | 1 (0-3)b | 5 (12.5) | 1 (2.5) | 0 | 0 | |
| Patel et al,30 2022 | US | 9 | 15.5 (14.5-16.6)b | 0 | 9 (100) | NA | NA | 1 (11.1) | 8 (88.9) | NA | NA | NA | NA | NA | 9 (100) | 2 (1-3)b | 2 (22.2) | NA | 0 | 0 | |
Abbreviations: ECMO, extracorporeal membrane oxygenation; EF, ejection fraction; ICU, intensive care unit; LGE, late gadolinium enhancement; LV, left ventricular; LOS, length of stay; NA, not available.
a
LV systolic dysfunction was defined as LV ejection fraction (LVEF) less than 55%; mild LV systolic function, as LVEF 45% to 54%; moderate, as LVEF 35% to 44%; and severe, as LVEF less than 35%.
b
Presented as median (IQR).